

Product Name: PF-06463922 Revision Date: 01/16/2020

### **Product Data Sheet**

### PF-06463922

Cat. No.: B4882


CAS No.: 1454846-35-5 Formula: C21H19FN6O2

M.Wt: 406.41Synonyms: lorlatinib

Target: Tyrosine Kinase

Pathway: ALK

Storage: Store at -20°C



# Solvent & Solubility

≥20.3mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.4606 mL	12.3028 mL	24.6057 mL
	5 mM	0.4921 mL	2.4606 mL	4.9211 mL
-10	10 mM	0.2461 mL	1.2303 mL	2.4606 mL

Please refer to the solubility information to select the appropriate solvent.

# **Biological Activity**

Shortsummary	ALK/ROS1 inhibitor,potent	ALK/ROS1 inhibitor,potent and selective		
IC <sub>50</sub> & Target				
In Vitro	Cell Viability Assay			
	Cell Line:	HCC78 cells harboring the SLC34A2-ROS1(S/L) proteins and BaF3 cells		
	Espore inc	engineered to express the CD74-ROS1 fusion		
	Preparation method:	The solubility of this compound in DMSO is >20.3mg/mL. General tips for		
		obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes		
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored		
		below -20°C for several months.		
	Reacting conditions:	0-10000 nM		

	Applications:	In HCC78 and BaF3 CD74-ROS1 cells, PF-06463922 potently inhibited cell		
		proliferation with IC50 values of 1.3 and 0.6 nM, respectively. PF-06463922		
		dose-dependently decreased phosphorylation of SLC34A2-ROS1 and		
		downstream signaling molecules SHP2, Erk1/2, and AKT in HCC78 cells.		
	Animal experiment			
	Animal models:	mice bearing FIG-ROS1 glioblastoma multiforme (GBM) tumors		
	Dosage form:	10 mg/kg/d; s.c. osmotic pumps; 3-, 7-, or 14-d treatment		
	Applications:	In mice bearing FIG-ROS1 GBM tumors, PF-06463922 significantly regressed		
		the GBM LSL-FIG-ROS1;Cdkn2a-/-;LSL-Luc tumors following a 7-d and 14-d		
In Vivo		treatment. PF-06463922 reduced overall tumor cell size and the number of		
		Ki67-positive cells. PF-06463922 reduced pFIG-ROS1, pSHP2, pMEK1/2, and		
		pERK1/2 in tumor cell lysates.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
		slightly differ with the theoretical value. This is caused by an experimental		
	10.	system error and it is normal.		

## **Product Citations**

See more customer validations on www.apexbt.com.

#### References

[1]. Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proceedings of the National Academy of Sciences, 2015, 112(11): 3493-3498.

#### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

### **APExBIO Technology**

#### www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com











